3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
6
Phase 3
3
Phase 2/3
1
Phase 2
1
Status
Completed
3
Active not recruiting
3
Terminated
1
Not yet recruiting
1
Sponsor Class
INDUSTRY
2
OTHER_GOV
1
Study Type
Interventional
3
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Peritoneal Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Fallopian Tube Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
Cyclophosphamide
299
Cisplatin
298
Paclitaxel
257
Radiotherapy
255
Fluorouracil
234
Carboplatin
234
Docetaxel
230
Doxorubicin
216
Dexamethasone
166
Gemcitabine
156
Vincristine
147
Etoposide
136
Leucovorin
133
Capecitabine
129
Bevacizumab
129
Prednisone
125
Rituximab
118
Methotrexate
118
Cytarabine
110
Filgrastim
99
Trastuzumab
97
Oxaliplatin
96
pembrolizumab
83
Pemetrexed
73
Epirubicin
70
Tamoxifen
69
Drug Therapy
69
Irinotecan
65
Granulocyte Colony-Stimulating Factor
60
Daunorubicin
58
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Phase 3
×
Completed
×
Glucose
×
Clear all
NCT03740165
2026-05-04
KEYLYNK-001
Merck Sharp & Dohme LLC
Phase 3
Completed
1,367 enrolled
29 charts
NCT04799249
2024-08-01
PRESERVE 2
G1 Therapeutics, Inc.
Phase 3
Completed
194 enrolled
NCT01836575
2013-04-22
PS2
Instituto Nacional de Cancer, Brazil
Phase 3
Completed
228 enrolled